Clinical trials: Immune-Inflammatory
- Condition Immune-Inflammatory
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Healthy, Primary Immune Thrombocytopenia
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
This phase 1 single ascending dose study will provide a first in human assessment of safety and tolerability of PF-06755347 in healthy adult males as well as adult males and females with Immune Thrombocytopenia (ITP).
- Conditions
- Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Trial name
- NCT03275740
- Testing
- PF-06755347 intravenous healthy participant, PF-06755347 subcutaneous healthy participant, PF-06755347 subcutaneous ITP
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Graft-versus-Host Disease (cGVHD)
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants
The primary objective of this study is to characterize the pharmacokinetics (PK) profile of a single dose of AMG 592 administered subcutaneously in healthy Japanese participants.
- Trial name
- NCT05885451
- Testing
- AMG 592
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy, Idiopathic Inflammatory Myopathies
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with autoimmune diseases.
- Conditions
- Healthy, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjögren's Disease
- Trial name
- NCT07284797
- Testing
- XmAb657
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xencor, Inc.
Immune Mediated Inflammatory Diseases
A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male Participants
The immune system helps protect the body from diseases. But, sometimes the immune system can be too sensitive and overreact to very small allergens, like dust and pet dander.
- Trial name
- NCT05003089
- Testing
- BAY1834845, BAY1830839, Prednisolone
- Where
- Netherlands
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Bayer
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Inflammatory Bowel Disease
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
The primary purpose of this study is to determine the rates of seroconversion to a hepatitis B vaccine series after a single 750 mg intravenous (IV) dose of vedolizumab or placebo.
- Trial name
- NCT01981616
- Testing
- Vedolizumab, Hepatitis B vaccine, Oral cholera vaccine
- Where
- United Kingdom
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Psoriatic Arthritis, Rheumatoid Arthritis
Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis
This study is designed to investigate whether non-invasive ultrasound (US) that is optimized for stimulation and can elicit an anti-inflammatory response in people with Inflammatory Arthritis as compared to a sham intervention.
- Conditions
- Psoriatic Arthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- NCT06555562
- Testing
- Ultrasound Stimulation, Non-active ultrasound stimulation
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Surf Therapeutics
Arthritis, Rheumatoid
Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects
This exploratory study aims to assess exposure of healthy subjects to systemic challenge with either LPS or GM-CSF. This will be done by measuring inflammatory mediators and cellular activation markers both in circulation and in…
- Trial name
- NCT03306589
- Testing
- Cantharidin, Lipopolysaccharide, Granulocyte-Macrophage Colony-Stimulating Factor
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent of patients don't respond to current treatments.
- Trial name
- NCT02480946
- Testing
- MBS2320, Methotrexate
- Where
- 3 sites in United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Modern Biosciences Ltd
Atopic Dermatitis
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and…
- Trial name
- NCT04668066
- Testing
- PF-07242813
- Where
- 7 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma
A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma
This is a first in human clinical study. Part 1 of the clinical study will assess the safety and tolerability, as well as the single dose pharmacokinetics (PK), of inhaled AZD4604 in healthy volunteers (Part 1a, single ascending…
- Trial name
- NCT04769869
- Testing
- AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus, Arthritic Psoriasis
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165…
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03254784
- Testing
- BMS-986165 Capsule, BMS-986165 Tablet
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Sjogren's Syndrome
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
- Trial name
- NCT00631358
- Testing
- Maxidex, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Alcon Research
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Venous Thromboses, Venous Thromboembolism
The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Blood clots occurring in the legs and in the lungs are relatively common; they occur in around 3 in a 1000 people per year. They can cause disability and are also potentially life threatening.
- Conditions
- Venous Thromboses, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT03835780
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 266,890 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Inflammatory Response
Inflammatory and Immune Response After High Intensity Exercise
This double-blinded, randomized, placebo-controlled, cross-over study is designed to evaluate the potential effects of a fucoidan supplement on the inflammatory and immune responses following high intensity exercise.
- Trial name
- NCT05277727
- Testing
- Fucoidan 500mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Marinova Pty Ltd
Healthy Subjects
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects
This study is a first-in-human phase I randomised, double-blind, placebo-controlled, evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single (IV and SC) and Multiple (IV only)…
- Trial name
- NCT03980080
- Testing
- OSE-127
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- OSE Immunotherapeutics
Hereditary Angioedema (HAE)
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.
- Trial name
- NCT02045264
- Testing
- Icatibant (30 mg)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shire